Targeting PML/RARalpha transcript with DNAzymes results in reduction of proliferation and induction of apoptosis in APL cells.
Kabuli
Majid
M
Molecular Oncology Group, University Department of Haematology, Manchester Royal Infirmary, Manchester, UK.
Yin
John Ahman Liu
JA
Tobal
Khalid
K
D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D020029:Base Pairing; D015153:Blotting, Western; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor / Q000737:chemistry / Q000187:drug effects; D002474:Cell-Free System; D021881:DNA, Catalytic / Q000008:administration & dosage / Q000494:pharmacology*; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D018390:Gene Targeting; D006801:Humans; D006868:Hydrolysis; D020014:K562 Cells / Q000737:chemistry / Q000187:drug effects; D015473:Leukemia, Promyelocytic, Acute / Q000473:pathology*; D008081:Liposomes / Q000008:administration & dosage; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000235:genetics*; D009690:Nucleic Acid Conformation; D015514:Oncogene Proteins, Fusion / Q000037:antagonists & inhibitors / Q000235:genetics*; D012333:RNA, Messenger / Q000037:antagonists & inhibitors* / Q000235:genetics; D012334:RNA, Neoplasm / Q000037:antagonists & inhibitors* / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013379:Substrate Specificity; D014162:Transfection; D014212:Tretinoin / Q000494:pharmacology
D000970:Antineoplastic Agents; D021881:DNA, Catalytic; D008081:Liposomes; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D012333:RNA, Messenger; D012334:RNA, Neoplasm; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D014212:Tretinoin